Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/264386
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters |
Autor: | Boudewijns, Robbert; Pérez, Patricia; Lázaro-Frías, Adrián; Van Looveren, Dominique; Vercruysse, Thomas; Thibaut, Hendrik Jan; Weynand, Birgit; Coelmont, Lotte; Neyts, Johan; Astorgano, David; Montenegro, Dolores; Puentes, Eugenia; Rodríguez, Esteban; Dallmeier, Kai; Esteban, Mariano CSIC ORCID ; García-Arriaza, Juan CSIC ORCID | Palabras clave: | SARS-CoV-2 COVID-19 MVA vaccine Spike Hamsters Immunogenicity Efficacy |
Fecha de publicación: | 16-mar-2022 | Editor: | Frontiers Media | Citación: | Frontiers in Immunology 13: 845969 (2022) | Resumen: | To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials. | Versión del editor: | https://doi.org/10.3389/fimmu.2022.845969 | URI: | http://hdl.handle.net/10261/264386 | DOI: | 10.3389/fimmu.2022.845969 | E-ISSN: | 1664-3224 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (CNB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
fimmu-13-845969.pdf | 8,38 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
13
checked on 29-mar-2024
WEB OF SCIENCETM
Citations
13
checked on 22-feb-2024
Page view(s)
93
checked on 29-mar-2024
Download(s)
63
checked on 29-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons